Far Infrared Radiation Treatment of Dementia and Other Mental Illness

Dementia Clinical Trial

Official title:

Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Dementia and Other Related Mental Illness.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00574054
• Other study ID #: GAAD-DEM-CTP1
• Status: Active, not recruiting
• Phase: Phase 1
• First received: December 12, 2007
• Last updated: August 14, 2009
• Start date: February 2008
• Est. completion date: March 2009

Study information

• Verified date: August 2009
• Source: GAAD Medical Research Institute Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

This trial is a preliminary study to determine the use of far infrared radiation for the treatment of dementia and other mental sickness.

Description:

Dementia is the progressive decline in cognitive function due to damage or disease in the brain beyond what might be expected from normal aging. Particularly affected areas include memory, attention, language, and problem solving. Especially in the later stages of the condition, affected persons may be disoriented in place and in person (not knowing who they are).

The prevalence of dementia is rising as the global life expectancy is rising. Particularly in Western countries, there is increasing concern about the economic impact that dementia will have in future, older populaces.

It is a disease that is strongly associated with age; 1% of those aged 60-65, 6% of those aged 75-79, and 45% of those aged 95 or older suffer from the disease.

We are postulating that the use of far infrared radiation on the central nervous system, the endocrine system and the viscera will have a positive effect on treating dementia and other neurological illnesses.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 4
• Est. completion date: March 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• Persons age 2 or older, with dementia, Alzheimer's, Huntington's disease, Parkinson's disease, Down's syndrome, multiple sclerosis or stroke

Exclusion Criteria:

• Persons with severe mental illness that are confined to mental hospitals etc., as defined by the USA Diagnostic and Statistical Manual of Mental Disorders (DSM)

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dementia
• Mental Disorders

Intervention

Radiation:
• Far Infrared
Far infrared radiation (5 µm to 20 µm wavelength) for 30 to 40 minutes per treatment session.

Locations

Country	Name	City	State
Canada	The Centre for Incurable Diseases	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
GAAD Medical Research Institute Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary end point is to determine the therapeutic effects of far infrared radiation on dementia.		1 year	No
Secondary	The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other related mental illness including Alzheimer's, multiple sclerosis and stroke rehabilitation.		1 year	No